Delving into the Latest Updates on Biomedical Research Institute of Jiangsu Wuzhong Medicine Group Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Recombinant protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Recombinant protein	1

Top 5 Target	Count

Protein kinases	1

The primary objective was to investigate the tolerability of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors. The secondary objective was to evaluate the pharmacokinetic characteristics of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors.

Start Date12 Dec 2016

Sponsor / Collaborator

Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.

[+1]

100 Clinical Results associated with Biomedical Research Institute of Jiangsu Wuzhong Medicine Group Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Biomedical Research Institute of Jiangsu Wuzhong Medicine Group Co., Ltd.

Login to view more data

100 Deals associated with Biomedical Research Institute of Jiangsu Wuzhong Medicine Group Co., Ltd.

Login to view more data

100 Translational Medicine associated with Biomedical Research Institute of Jiangsu Wuzhong Medicine Group Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Login to view more data